(Q53476120)

14 May 2018

title

Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. (English)

1 reference

14 May 2018

main subject

mesenchymal stem cell

1 reference

1

1 reference

14 May 2018

author name string

Federica M Marelli-Berg

series ordinal

2

1 reference

14 May 2018

language of work or name

English

0 references

publication date

1 June 2008

1 reference

14 May 2018

European Journal of Immunology

published in

1 reference

14 May 2018

volume

38

1 reference

14 May 2018

issue

6

1 reference

14 May 2018

page(s)

1479-1482

1 reference

14 May 2018

The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

Immunoregulatory function of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatc

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Potential of mesenchymal stem cell therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838433

7 January 2021

Identifiers

DOI

10.1002/EJI.200838433

1 reference

14 May 2018

1 reference

14 May 2018